Verrica Pharmaceuticals Inc (NAS:VRCA)

$ 8.56 0.21 (2.51%) Market Cap: 363.12 Mil Enterprise Value: 360.62 Mil PE Ratio: 0 PB Ratio: 237.78 GF Score: 46/100

Q1 2024 Verrica Pharmaceuticals Inc Earnings Call Transcript
May 13, 2024

$9.56 (+19.50%)

Earnings
Q4 2023 Verrica Pharmaceuticals Inc Earnings Call Transcript
Feb 29, 2024

$5.27 (-7.87%)

Earnings
Q3 2023 Verrica Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2023

$3.21 (-9.83%)

Earnings
Verrica Pharmaceuticals Inc to Host KOL Event (Virtual) Transcript
Oct 11, 2023
Verrica Pharmaceuticals Inc to Discuss FDA Approval of YCANTH Call Transcript
Jul 24, 2023
Verrica Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
Verrica Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 17, 2023
Verrica Pharmaceuticals Inc at Cowen Health Care Conference Transcript
Mar 06, 2023
Verrica Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 14, 2022
Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021
Verrica Pharmaceuticals Inc VIRTUAL PANEL: The Pursuit of Molluscum - Beetlejuice and Nobel Prizes Transcript
Sep 22, 2020

Verrica Pharmaceuticals Inc at Cowen Health Care Conference Transcript

Mar 06, 2023 / 07:50PM GMT

Release Date Price: $7.27 (+0.83%)

Transcript 10-K8-K

Stacy Ku

Cowen and Company, LLC - Analyst

My name is Stacy Ku, one of the biopharma analysts, and I'm here with my colleague, Georgi Yordanov. I'd like to welcome Ted White, CEO of Verrica Pharmaceuticals; and Joe Bonaccorso, the Chief Commercial Officer to our fireside chat. Thank you so much for joining us today.

Ted White

Verrica Pharmaceuticals Inc. - President & CEO

Thank you.

Stacy Ku

Cowen and Company, LLC - Analyst

So we're very excited to discuss the potential and impending launch of YCANTH in July for molluscum contagiosum. I think you had the NDA resubmission last week. And with that, we'll dive right into Q&A.

Questions & Answers

Stacy Ku

Cowen and Company, LLC - Analyst

So for those that are not familiar, can you just very broadly describe your product, VP-102 or YCANTH and then provide some brief background on molluscum contagiosum?

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.